Cadila Healthcare Limited, India developed a candidate vaccine ZyCoV-D comprising of a DNA plasmid vector carrying the gene encoding the spike protein (S) of the SARS-CoV-2 virus. (S) protein, following immunization with three doses adminis- tered 28 days apart. Neutralizing antibody response was also demonstrated against wild type SARS-CoV-2 strain, which may play a substantial role in viral clearance and mitigation of human clinical disease. Implications of all the available evidence Many vaccine candi- dates are in rapid development, including recombinant-protein based vaccines, replicating or non-replicating viral vector- based vaccines, DNA vaccines, and mRNA vaccines (which mostly have focused on the spike glycoprotein or receptor binding domain), live attenuated vaccines, and inactivated virus vaccines. Our findings indicate that DNA vaccine is safe and immunogenic in healthy adults. ZyCoV-D® vaccination course consists of three separate doses of 0.2 ml each. ZyCoV-D® vaccinat